Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0E2SW)

• Drug Name: PF-07257876 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DM0E2SW

Molecule-Related Drug Atlas

Drug(s) Targeting Leukocyte surface antigen CD47 (CD47)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hu5F9-G4	DMBER0Q	Myelodysplastic syndrome	2A37	Phase 3	[2]
Evorpacept	DMJTX7Q	Gastric cancer	2B72	Phase 2/3	[3]
PF-07901801	DMEVYHR	Diffuse large B-cell lymphoma	2A81	Phase 2	[4]
ALX148	DMGQX0U	Myelodysplastic syndrome	2A37	Phase 1/2	[2]
DSP-107	DM8K0PR	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[5]
AO-176	DMXU98C	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[6]
TG-1801	DM3K4FY	B-cell lymphoma	2A86	Phase 1	[7]
SL-172154	DMN3D72	Ovarian cancer	2C73	Phase 1	[8]
TTI-621	DMDNPAV	Haematological malignancy	2B33.Y	Phase 1	[9]
TTI-622	DMOCQ4K	Lymphoma	2A80-2A86	Phase 1	[10]

Drug(s) Targeting Programmed cell death 1 ligand 1 (PD-L1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Avelumab	DMSZLJR	Merkel cell carcinoma	2C34	Approved	[11]
Durvalumab	DM4PVDY	Urothelial carcinoma	2C92.0	Approved	[12]
RG-7446	DM69XMQ	Urothelial carcinoma	2C92.0	Approved	[13]
Bavencio	DMU9C8F	Merkel cell carcinoma	2C34	Approved	[14]
Atezolizumab	DMMF8U0	Non-small-cell lung cancer	2C25	Approved	[15]
Sugemalimab	DMH5YQ3	Non-small-cell lung cancer	2C25	Approved in China	[16]
KN046	DMSDBPG	Non-small-cell lung cancer	2C25.Y	Phase 3	[17]
MEDI4736	DM5X849	Solid tumour/cancer	2A00-2F9Z	Phase 3	[18]
MPDL-3280A	DM9K3LM	Melanoma	2C30	Phase 3	[19]
CS1001	DMSY0NE	Non-small-cell lung cancer	2C25	Phase 3	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leukocyte surface antigen CD47 (CD47)	TT28S46	CD47_HUMAN	Not Available	[1]
Programmed cell death 1 ligand 1 (PD-L1)	TT8ZLTI	PD1L1_HUMAN	Not Available	[1]

References

• [1] ClinicalTrials.gov (NCT04881045) A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07257876 IN PATIENTS WITH ADVANCED OR METASTATIC TUMORS. U.S.National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2021 Dec;22(12):1740-1751.
• [4] ClinicalTrials.gov (NCT05626322) A PHASE 1b/2 STUDY OF PF-07901801, A CD47 BLOCKING AGENT, WITH TAFASITAMAB AND LENALIDOMIDE FOR PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION. U.S.National Institutes of Health.
• [5] Clinical pipeline report, company report or official report of KAHR Medical.
• [6] Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding. Mol Cancer Ther. 2020 Mar;19(3):835-846.
• [7] Clinical pipeline report, company report or official report of TG Theraputics.
• [8] Clinical pipeline report, company report or official report of Shattuck Labs.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Clinical pipeline report, company report or official report of Trillium Therapeutics.
• [11] Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-57.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [13] PD-1 as a potential target in cancer therapy. Cancer Med. 2013 October; 2(5): 662-673.
• [14] ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health.
• [15] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [16] Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.
• [17] Clinical pipeline report, company report or official report of Alphamab Oncology.
• [18] National Cancer Institute Drug Dictionary (drug id 740856).
• [19] Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol. 2014 May 10; 5(2): 39-47.
• [20] GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015.